<DOC>
	<DOCNO>NCT00109707</DOCNO>
	<brief_summary>The purpose trial ass efficacy , safety , tolerability , biologic activity , pharmacokinetics AMN107 six group patient one follow condition : Relapsed/refractory Ph+ Acute lymphoblastic leukemia ( ALL ) ( arm 1 ) Group A - Imatinib failure ( arm 2 , 3 4 ) - imatinib-resistant intolerant CML - Chronic Phase ( CP ) - imatinib-resistant intolerant CML - Accelerated Phase ( AP ) - imatinib-resistant intolerant CML - Blast Crisis ( BC ) Group B - Imatinib TKI failure ( arm 2 , 3 4 ) - imatinib-resistant intolerant CML - Chronic Phase ( CP ) - imatinib-resistant intolerant CML - Accelerated Phase ( AP ) - imatinib-resistant intolerant CML - Blast Crisis ( BC ) Hypereosinophilic syndrome/chronic eosinophilic leukemia ( HES/CEL ) ( arm 5 ) Systemic mastocytosis ( Sm ) ( arm 6 )</brief_summary>
	<brief_title>A Study Oral AMN107 Adults With Chronic Myelogenous Leukemia ( CML ) Other Blood Related Cancers</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Main inclusion criterion include : Patients CML blast crisis , CML accelerate phase define never blast crisis phase , CML chronic phase define never blast crisis phase accelerate phase : *developed progressive disease therapy least 600 mg imatinib per day , OR *patients CML imatinib therapy , dose , develop progressive disease presence genetic mutation likely result imatinib resistance OR *have develop intolerance imatinib Relapsed refractory Ph+ ALL Hypereosinophilic syndrome/chronic eosinophilic leukemia . Systemic mastocytosis clinical indication treatment . Prior imatinib therapy patient Ph+ ALL , HES/CEL SM permit require CML patient treat investigational tyrosine kinase inhibitor otherwise meet definition imatinibresistance intolerance eligible Written inform consent prior study procedure perform Impaired cardiac function Patients severe/chronic uncontrolled medical condition ( include limit diabetes , infection , GI impairment , CNS infiltration , liver kidney disease ) Prior concomitant use certain medication ( include limit warfarin , chemotherapy , hematopoietic colonystimulating growth factor , medication affect electrocardiogram test result , investigational drug ) Women pregnant breastfeeding Patients history another primary malignancy currently clinically significant currently require active intervention . Patients unwilling comply protocol . Known diagnosis human immunodeficiency virus ( HIV ) infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CML blast crisis</keyword>
	<keyword>CML chronic phase</keyword>
	<keyword>CML accelerate phase</keyword>
	<keyword>Gleevec resistance</keyword>
	<keyword>Gleevec intolerant</keyword>
	<keyword>Gleevec CML</keyword>
	<keyword>imatinib resistance</keyword>
	<keyword>imatinib intolerant</keyword>
	<keyword>Hypereosinophilic Syndrome</keyword>
	<keyword>Systemic Mastocytosis</keyword>
	<keyword>Chronic eosinophilic syndrome</keyword>
	<keyword>Philadelphia chromosome positive acute lymphoblastic leukemia</keyword>
	<keyword>HES</keyword>
	<keyword>CEL</keyword>
	<keyword>CML</keyword>
	<keyword>SM</keyword>
	<keyword>Ph+ ALL refractory standard therapy</keyword>
	<keyword>Ph+ALL relapse</keyword>
	<keyword>AMN107A</keyword>
</DOC>